Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$22.59M

FY 2025 · Annual

Investing Cash Flow

-$5.24M

FY 2025 · Annual

Financing Cash Flow

$45.34M

FY 2025 · Annual

+630.1% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.46M)(7.38M)(7.96M)(43.32M)
Depreciation & Amortization0002.36M
Deferred Income Tax0000
Stock-Based Compensation110.15K1.73M1.8M0
Change in Working Capital640.86K2.05M34.63K(6.07M)
Accounts Receivables00(45.79K)(8.81M)
Inventory0001.78M
Accounts Payables413.6K1.63M1.18M1.36M
Other Working Capital227.26K424.07K(1.1M)(395K)
Other Non-Cash Items140.43K2.62M328.93K24.44M
Operating Cash Flow(1.57M)(981.03K)(5.79M)(22.59M)
Capital Expenditures000(99K)
Acquisitions (Net)000(5.14M)
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow000(5.24M)
Debt Repayment400K766.94K321.43K17.75M
Common Stock Issued0255.41K6.05M27.59M
Common Stock Repurchased00(166.51K)0
Dividends Paid0000
Other Financing Activities1.22M000
Financing Cash Flow1.62M1.02M6.21M45.34M
Effect of Forex Changes000(443)
Net Change in Cash55.07K41.32K417.05K17.51M
Free Cash Flow(1.57M)(981.03K)(5.79M)(22.69M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$43.3M
+ D&A$2.4M
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$6.1M
+ Other Non-Cash$24.4M
= Operating Cash Flow-$22.6M
- Capex-$99.0K
= Free Cash Flow-$22.7M

Analysis

FY2025 free cash flow is -$22.7M. FCF conversion is 52.4% of net income. Operating cash flow was -$22.6M, with capex of -$99.0K. The largest bridge item is Other Non-Cash at $24.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportMay 28, 2026
4Statement of changes in beneficial ownershipMay 26, 2026
144Notice of proposed sale of securitiesMay 22, 2026
8-KCurrent reportMay 21, 2026
4Statement of changes in beneficial ownershipMay 18, 2026

Does PTHS generate free cash flow?

Pelthos Therapeutics Inc. (PTHS) generated -$22.69M of free cash flow in fiscal 2025.

How much operating cash flow does PTHS produce?

Operating cash flow was -$22.59M, before capital expenditures of $99,000.00.